The biologics industry is facing increased complexity as pipelines expand beyond monoclonal antibodies to include multispecific antibodies, fusion proteins, and viral vectors. This evolution presents significant challenges in maintaining momentum from early development through GMP manufacturing. Unlike traditional models, which relied on established processes, today’s biologics often require bespoke manufacturing strategies and customized analytical methods. Early decisions in development can have long-term implications for technology transfer and scalability.
Emerging biotechnology companies face heightened pressure to adapt as clinical data evolves and regulatory expectations increase. The transition from development to manufacturing is particularly vulnerable, often leading to delays when scientific understanding is not effectively communicated during technology transfer. Fragmentation in outsourcing can exacerbate these issues, resulting in operational, technical, and organizational costs that extend timelines. To mitigate these challenges, a new development philosophy that prioritizes commercial manufacturing requirements from the outset is essential. This integrated approach can enhance agility and support successful outcomes in biologics development.
Source: contractpharma.com · Image: Hooping of the curd, Mount Tyson Co-op Dairy Association Cheese Factory, November 1951 by Queensland State Archives, Public domain, via Wikimedia Commons
Open the full market picture for your next decision →
